Hematologic Malignancy
Mature B-Cell Non-Hodgkin Lymphoma
CI-CAN-00003259Explore in graph →
Hematologic792 active trials17 approved drugs43 evidence items
- NCIt
- C7056
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003259Explore in graph →
Clinical trials
2,506 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (393)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05776160 | Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel | available | — | — | Kite, A Gilead CompanyINDUSTRY | 2 | Jun 12, 2026 | clinicaltrials |
| NCT05776134 | Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel | available | — | — | Kite, A Gilead CompanyINDUSTRY | 1 | Apr 8, 2026 |
| clinicaltrials |
| NCT07215832 | Karyopharm Expanded Access Program for Selinexor(KEAP) | available | — | — | Karyopharm Therapeutics IncINDUSTRY | 0 | Mar 2, 2026 | clinicaltrials |
| NCT05619367 | A Compassionate Use (CU) Program of Odronextamab | available | — | — | Regeneron PharmaceuticalsINDUSTRY | 0 | Dec 23, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jun 12, 2026source: clinicaltrials